All News
That's not my problem - or is it? Multimorbidity in RA
Traditionally, rheumatologists have often been deferential to the non-articular concerns in RA to other providers, though these issues are often left unaddressed. What role do rheumatologists have in the management of multimorbidity in our patients?
Read Article
Will AI put me out of a job?
The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".
Read Article
Obinutuzumab Efficacy in Active Lupus Nephritis
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
Read Article
“Preventing” Arthritis in Psoriasis
The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.
Read Article
“Preventing” Arthritis in Psoriasis
Prevention of the development of our systemic rheumatic diseases in individuals deemed at risk, or with some form of precursor disease process, has been a hot topic in recent years.
https://t.co/nGKGUkKVUl https://t.co/PruJZLAq9n
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
AI models require good Positive Predictive Value (PPV) But: PPV decreases as prevalence decreases - In choosing a successful biologic: Harder to predict more challenging patients (multiple failures, co-morbidities, etc) - ACR50 non-response is higher J… https://t.co/eAOR0jFmO3 https://t.co/TB6Ecd8nZh
Dr. John Cush RheumNow ( View Tweet)
Adela Castro @AdelaCastro222
How can AI be useful for RA pts and rheumatologists? -AI models have the potential for improving diagnosis, management and outcomes in RA pts. -Can also improve efficiency and clinic workflow. -Not so perfect as it sounds (hallucinations, limited… https://t.co/YA4A990p2v https://t.co/YnHtbP83Nm
Dr. John Cush RheumNow ( View Tweet)
Dr Rhee @RennieRhee mimics of medium/large vessel vasculitis. Increase in cross-sectional imaging use has increased the number of these we get referred. Segmental arterial mediolysis also pops up a fair bit. @RheumNow #RNL2025 https://t.co/yozRGE9Ncl
Richard Conway RichardPAConway ( View Tweet)
ICYMI: Treatment of sclerosing skin disease:
-Progression: inflammation➡️sclerosis➡️ atrophy
-Existing therapies target inflammation not sclerosis-poorly developed ttx for sclerosis
-First aspect is determining disease state, depth of involvement, extracutaneous manifestations… https://t.co/lYQRW2yDRG https://t.co/DQZjYKS2Ks
Links:
Adela Castro AdelaCastro222 ( View Tweet)
🆕 slide from @Official_ASAS
HLA-B27 strongly associated with Anterior #Uveitis in #SpA
#AAU #AxSpA #B27 https://t.co/lq19vIys9x
Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
@RichardPAConway on PMR
#RNL2025 @RheumNow
PMR mimics: look for mimics in unusual/refractory cases
- Suspect the mimics to avoid undertreatment or over-treatment
Conway: PMR is NOT easy. Easy to misdiagnosis, easy to mistreat. "One of our most challenging cases" https://t.co/WqPWwCuutF
Eric Dein ericdeinmd ( View Tweet)
Eric Dein @ericdeinmd
🏈Kick-off of @RheumNow w Jeff Curtis #RNL2025 🏈 AI in RA? Can help with Rheum Boards Questions, though AI is not confident in answers May not be better than paper charts for triage Other roles: pt chatbot, AI scribe, research populations, generate DDx,… https://t.co/3vJ2gON6tR https://t.co/3ArtaRkhJp
Dr. John Cush RheumNow ( View Tweet)
TheDaoIndex @KDAO2011
Potential uses of #AI for #RA -office workflow (scribe, triage) -research (match eligible pts for trials) -help with diagnosis (and likelihood of risk) -consume guidelines for disease mgmt @RADoctor #RNL2025 https://t.co/k2nOytpKBH https://t.co/7Y2OvBv9pP
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Recurrent Acute Oligoarthritis Recurrent Acute Oligoarthritis in a 40 yr. old man https://t.co/5D5qE05u1w https://t.co/tunU955MkH
Dr. John Cush RheumNow ( View Tweet)
Cannabis Hospitalizations and Mortality Risk
A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death.
https://t.co/MQtR3etpEH https://t.co/ZB4byi81on
Dr. John Cush RheumNow ( View Tweet)
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/5igpgtdE1U https://t.co/5KOXRThzlk
Dr. John Cush RheumNow ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Cather treatment options in HS. The last 2 obviously in rheumatology's wheelhouse @RheumNow #RNL2025 https://t.co/vGfvQH05lv
Richard Conway RichardPAConway ( View Tweet)
New for HS
- Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2
- Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE)
Clinical trials:
IL23 failed, ILalpha failed
Brodulamab (IL17a) clinically meaningful response
TNF trials
@RheumNow #ACR2025 https://t.co/BfzwNQ1wUB
Links:
Eric Dein ericdeinmd ( View Tweet)
The ‘dark’ side of
#Hidradenitis #suppurativa
👇
Smell of leaking lesions #HS
⬆️skin folds, buttock, axilla, also thighs, neck
⬆️depression
@RheumNow #RNL2025
‘ If pt doesn’t get in gown then not ready for systemic #Rx!’
Jennifer Clay
#ClinicalPearl https://t.co/tZzz5tielt
Links:
Janet Pope Janetbirdope ( View Tweet)